Analysts have been eager to weigh in on the Healthcare sector with new ratings on Global Blood Therapeutics (GBT) and Shockwave Medical (SWAV).
Global Blood Therapeutics (GBT)
In a report released today, John Newman from Canaccord Genuity maintained a Hold rating on Global Blood Therapeutics, with a price target of $60.00. The company’s shares closed last Monday at $65.84.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 17.6% and a 47.7% success rate. Newman covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Allogene Therapeutics, and Palatin Technologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $109.33 average price target.
See today’s analyst top recommended stocks >>
Shockwave Medical (SWAV)
In a report released yesterday, Cecilia Furlong from Canaccord Genuity maintained a Buy rating on Shockwave Medical, with a price target of $53.00. The company’s shares closed last Monday at $45.00.
According to TipRanks.com, Furlong is a 2-star analyst with an average return of 8.5% and a 80.0% success rate. Furlong covers the Healthcare sector, focusing on stocks such as TransMedics Group, Vapotherm, and Atricure.
Shockwave Medical has an analyst consensus of Moderate Buy, with a price target consensus of $43.60, representing a -3.3% downside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $54.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
